CU 04
Alternative Names: CU04Latest Information Update: 28 Aug 2024
Price :
$50 *
At a glance
- Originator CURACLE
- Class Antineoplastics; Immunotherapies
- Mechanism of Action Proto-oncogene protein c-myc inhibitors; Regulatory T-lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Solid tumours
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in Acute-myeloid-leukaemia in South Korea (PO)
- 28 Aug 2024 No recent reports of development identified for research development in Solid-tumours in South Korea (PO)
- 20 Jul 2020 Early research in Acute myeloid leukaemia in South Korea (PO) (Curacle pipeline, July 2020)